Screener
Gilead Sciences GILD Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $7.8B+10.2% | $6.96B+4.4% | $7.93B+4.7% | $7.77B+3.0% | $7.08B+1.8% | ||
| $1.58B+5.2% | $1.45B-6.2% | $1.62B+2.7% | $1.57B-0.3% | $1.5B-2.8% | ||
| $6.22B+11.5% | $5.52B+7.6% | $6.3B+5.2% | $6.2B+3.8% | $5.58B+3.2% | ||
| 79.8%+1.0pp | 79.2%+2.3pp | 79.5%+0.4pp | 79.8%+0.7pp | 78.8%+1.0pp | ||
| $1.76B+18.3% | —— | $1.58B-3.5% | $1.35B-3.5% | $1.49B+10.4% | ||
| $1.92B+40.7% | $1.45B+15.3% | $1.79B-5.9% | $1.36B-5.3% | $1.37B-0.9% | ||
| $18.2B+295% | $4.37B-1.3% | $5.94B+16.1% | $4.44B-33.3% | $4.61B+6.9% | ||
| -$10.39B-520% | $2.59B+15.6% | $1.98B-19.1% | $3.33B+275% | $2.47B-6.4% | ||
| -133.2%-168pp | 37.2%+3.6pp | 25%-7.4pp | 42.8%+31.1pp | 34.9%-3.1pp | ||
| $247M-2.8% | $240M-7.7% | $255M+2.4% | $256M+7.6% | $254M+7.2% | ||
| $387M+86.1% | $235M+172% | $349M— | $569M+85.9% | $208M+159% | ||
| -$10.25B-522% | $2.58B+56.5% | $2.08B-4.1% | $3.64B+281% | $2.43B+18.3% | ||
| $242M-48.3% | $559M+67.4% | $0-100% | $589M+298% | $468M+6.8% | ||
| -$10.5B-636% | $2.02B+53.7% | $2.18B+22.4% | $3.05B+144% | $1.96B+21.4% | ||
| -134.5%-162pp | 29%+9.3pp | 27.5%+4.0pp | 39.3%+22.7pp | 27.7%+4.5pp | ||
| -$8.45-642% | $1.61+54.8% | $1.74+22.5% | $2.43+143% | $1.56+20.9% | ||
| -$10.3B-501% | $2.68B+14.8% | $2.07B-18.6% | $3.42B+248% | $2.57B-6.4% | ||
| -131.9%-168pp | 38.5%+3.5pp | 26.2%-7.5pp | 44%+31.0pp | 36.2%-3.2pp | ||
| -$10.39B-520% | $2.59B+15.6% | $1.98B-19.1% | $3.33B+275% | $2.47B-6.4% |
FAQ
- What is Gilead Sciences's revenue?
- Gilead Sciences (GILD) generated $30.5B in revenue over the trailing twelve months, up 5.5% year over year.
- Is Gilead Sciences profitable?
- Gilead Sciences is not currently profitable: it reported a net loss of $3.2B over the trailing twelve months, a -10.6% net margin.
- What are Gilead Sciences's profit margins?
- Gross margin is 79.6% and operating margin is -8.2%, with a -10.6% net margin.
- What is Gilead Sciences's earnings per share?
- Gilead Sciences's diluted EPS over the trailing twelve months is $-2.67.
- Where does Gilead Sciences's income statement data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
